Related Experiment Videos
Construction and clinical validation of a cascaded deep learning system for classification of benign and malignant
MengQiu Cui1, ZiLong Zeng2, SiLu Chen3
1Department of Radiology, the First Medical Center, Chinese PLA General Hospital, No.28 Fuxing Road, Haidian District, Beijing 100853, China.
Objective:
This study aims to develop a cascaded deep learning (DL) system based on multiparametric MRI to establish an automated pipeline for the segmentation and classification of small renal masses (SRMs).
Materials And Methods:
A retrospective collection of SRM patients with pathologically confirmed from three institutions was conducted. MRI data from Institution 1 were randomly divided into a training set and an internal test set. Data from other institutions served as the external test set. A cascaded DL system was developed, incorporating automated segmentation and benign-malignant classification. Diagnostic performance was evaluated using receiver operating characteristic analysis and compared against three radiologists of varying experience.
Results:
A total of 965 patients with SRM were included. Institution 1 contributed 888 cases, with 712 used for training and 176 as an internal test set; Institutions 2 and 3 provided 77 cases as an external test set. The optimal classification model using automated segmentation labels achieved AUCs of 0.936 and 0.788 on internal and external test sets, respectively. Performance was comparable to models using manual segmentation (internal: 0.936 vs. 0.944, P = 0.671; external: 0.788 vs. 0.832, P = 0.629). On the external test set, the model performed comparably to the senior radiologist, while it significantly outperformed the senior radiologist on the internal test set. The model significantly outperformed the junior radiologist on both test sets. This finding remained consistent in the subgroup of tumors smaller than 3 cm.
Conclusion:
The cascaded DL system demonstrated robust performance across multiple centers, enabling non-invasive and efficient discrimination of SRM malignancy, showing promise as a clinical support tool.